A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors-Reference-Cited by-同舟云学术

A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors

Published:2022-11-08 Issue:12 Volume:27 Page:1881-1890
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Campos Susana^ORCID,Matulonis Ursula,Berlin Suzanne,Horowitz Neil,Liu Joyce,Krasner Carolyn,Hang Lee,Zarwan Corrine,Barry William,Colella Tina,Whalen Christen,Shoni Melina,Lundquist Christine,Birrer Michael J.,Penson Richard

Funder

Genentech

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-022-02247-0.pdf

Reference30 articles.

1. Garcia AA, Hirte H, Fleming G et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76–82

2. Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum–resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–5186

3. Penson RT, Dizon DS, Cannistra SA et al (2010) Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Mullerian tumors. J Clin Oncol 28:154–159

4. Gordon AN, Finkler N, Edwards RP et al (2005) Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15(5):785–792

5. Hirte H, Oza S, Swenerton K et al (2010) A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol 118(3):308–312